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Purpose: 
The primary objective of this study is to retrospectively review the 
relationship between vancomycin dosing strategy, age and attained 
vancomycin trough concentrations. 
Background: 
 •  Vancomycin is the drug of choice for empirical treatment of late-onset 
septicemia in preterm infants1,2
 •  Many barriers to develop an optimal dosing regimen in neonates3,4,5
	 	 	 –		High	interpatient	and	intrapatient	variablility	in	vancomycin	
pharmacokinetics
 •  Expert consensus guidelines recommend for more aggressive dosing 
and higher trough concentrations of vancomycin for  the treatment of 
methicillin-resistant Staphylococcus aureus (MRSA) infections6,7 
	 	 	 –		Guidelines	do	not	include	neonatal	population
	 	 	 –		Lack	of	guidance	on	utilization	of	trough	goals	of	15-20	mcg/ml	in	the	
neonate
•  Lack of consensus for optimal dosing of vancomycin in preterm and full 
term neonates
Study Design: 
 •  Retrospective chart review
 •  Inclusion Criteria:
	 	 	 –		All	neonatal	patients	[age	0	to	46	weeks	post-menstrual	age	(PMA)]		
	 	 	 –		Received	intravenous	(IV)	treatment	with	vancomycin	July	1,	2008	
to	June	30,	2013
	 	 	 –		Had	at	least	one	trough	concentration	that	was	obtained	0-90	
minutes	before	a	dose	at	steady	state		
•  Exclusion Criteria:
	 	 	 –		Received	IV	treatment	with	vancomycin	prior	to	June	30,	2008		
	 	 	 –		No	trough	concentration	reported	during	treatment.	
	 	 	 –		Age	greater	than	46	weeks	PMA
•  The primary outcomes of the study: 
	 	 	 –		Number	of	patients	achieving	a	target	trough	concentration	of	5-15	
mcg/ml	in	each	dosing	group	and	age	group	
	 	 	 –		Average	vancomycin	dose	necessary	to	achieve	the	target	trough	in	
each	age	group
Methods: 
 • Stratify patients into predetermined categories: 
	 	 	 –		Vancomycin	dosing	and	age	range	
 •  Assess relationship between categories
 •  Evaluate attainment of vancomycin concentrations within each category 
 •  Patient-specific information to be collected will include:   
	 	 	 –		Age	[PMA	and	Postnatal	age	(PNA)]	
	 	 	 –		Weight
	 	 	 –		Vancomycin	dose	and	frequency
	 	 	 –		Days	of	vancomycin	therapy
	 	 	 –		Measured	vancomycin	trough	concentrations
	 	 	 –		Timing	of	vancomycin	trough	concentrations
	 	 	 –		Location	of	infection	and	organism
	 	 	 –		Documentation	of	organism	eradication	via	cultures	or	clinical	
determination	by	the	neonatologist
	 	 	 –		Daily	serum	creatinine	from	drug	initiation	to	discontinuation
	 	 	 –		Presence	of	any	co-administered	nephrotoxic	drugs		
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